31 results about "Cardiac index" patented technology

A system for evaluating the cardiovascular system parameters using indicator dilution and non-invasive or minimally invasive detection methods is disclosed. Intravascular indicators are stimulated, and emissions patterns detected for computation of cardiac output, cardiac index, blood volume and other indicators of cardiovascular health.

The invention discloses a cardiac function evaluation method for athletes' accurate selection of materials, which comprises the following steps: 1) testing the stroke output volume SV of the athletes under test when they are at rest 1 and heart rate HR 1 , according to CO=SV×HR, calculate the resting cardiac output per minute CO 1 2) The tested athlete carries out the quantitative load cardiovascular function exercise experiment set, and the average anaerobic work PP is measured; 3) The tested athlete is tested immediately after completing the exercise in step 2), and the daily PP immediately after the exercise is measured. Gaussian output SV 2 and heart rate HR 2 , to calculate the CO per minute immediately after exercise 2 ; 4) Calculate the heart index CI at rest according to the heart index CI=per minute cardiac output CO / body surface area BSA 1 and CI 2 ; 5) Calculating the Cardiac Reserve Index CRI: CRI=K*PP / (CI 2 ‑CI 1 ), the CRI value is positively correlated with the cardiac reserve capacity, and based on this, a more accurate quantitative evaluation of the cardiac function level of the tested athletes can be made.

A method includes receiving cardiac data and determining a cardiac index based upon the cardiac data; determining an increased risk of death associated with epilepsy if the indices are extreme, issuing a warning of the increased risk of death and logging information related to the increased risk of death. A second method comprises receiving at least one of arousal data, responsiveness data or awareness data and determining an arousal index, a responsiveness index or an awareness index, where the indices are based on arousal data, responsiveness data or awareness data respectively; determining an increased risk of death related to epilepsy if indices are extreme values, issuing a warning of the increased risk of death and logging information related to the increased risk of death. A non-transitory computer readable program storage device encoded with instructions that, when executed by a computer, perform a method is also provided.

A stethoscope front-end recorder device (also referred to as Sleeve) for the chest piece of a stethoscope, which is easily installed and removed. The Sleeve covers the circumference of the chest piece of a stethoscope. The Sleeve contains sensors for acquiring biosensor parameters such as electrocardiogram, body temperature, heartbeat, heart rhythm, heart rate variability, heart rate turbulence, heart sounds, respiration, cardiac index and blood flow. The Sleeve has Bluetooth interface communicating with a mobile device with software component, interfacing with a back-end server with the capability to capture, analyze and save patient information.

The invention discloses a medicine composition with active components of carvedilol and a medicinal salt thereof, and fimasartan. The invention also relates to an application of the medicine composition in treating hypertension and complications thereof, and an application of the medicine composition in treating congestive cardiac failure. In the medicine composition, a weight ratio of carvedilol and medicinal salt thereof to fimasartan is 1:0.01-1000. The components of the medicine composition are clear. When the medicine composition is used for treating hypertension and complications thereof, a substantial synergetic effect of the two medicine components is shown, and stable reduction of blood pressure can be realized; when the medicine composition is used for treating congestive cardiac failure, various cardiac indexes are substantially enhanced, a treatment effect is substantial, and a substantial synergetic effect of the two medicine components is shown.

The invention discloses new application of sodium houttuyfonate in pharmacy, in particular to the application of the sodium houttuyfonate in preparing medicaments for preventing and treating myocardial hypertrophy and / or ventricular hypertrophy. The application is to prepare an in-vitro myocardial cell hypertrophyby adopting three methods of preparing an in-vivo animal model of myocardial hypertrophy and ventricular hypertrophy, culturing a myocardial cell in vitro and inducing epinephrine by isoproterenol, L-thyroxine and abdominal aorta banding. Experiment results prove that the sodium houttuyfonate can reduce the increase of left cardiac index and global cardiac index of a model animal, inhibit hypertrophy of an in-vitro myocardial cell, reduce the cAMP concentration of plasma, the content of Ang II and ET-1 of a myocardial tissue and the content of TNF-alpha and ALD of serum, and can reduce blood pressure and decrease heart rate. Experiment results suggest that the sodium houttuyfonate has the functions of resisting myocardial hypertrophy and ventricular hypertrophy, and the mechanism of the sodium houttuyfonate can be related to the inhibition of sympathetic activity, blockage of system activity of feritin-hypertensin-aldosterone, and effect of endocrine factors.